MNPR Monopar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNPR

Price (delayed)

$59.81

Market cap

$400.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.93

Enterprise value

$348.26M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 13

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of ...

Highlights
The equity has soared by 153% YoY
Monopar Therapeutics's quick ratio has soared by 53% YoY and by 9% from the previous quarter
The EPS has soared by 52% YoY but it has contracted by 4.3% from the previous quarter
The net income has grown by 10% year-on-year but it has declined by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.monopartx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of MNPR

MNPR stock price

How has the Monopar Therapeutics stock price performed over time
Intraday
-1.24%
1 week
-7.17%
1 month
9.46%
1 year
68.05%
YTD
-8.41%
QTD
9.16%

Financial performance

How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.71M
Net income
-$14.98M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 12% from the previous quarter and by 6% YoY
The net income has grown by 10% year-on-year but it has declined by 9% since the previous quarter

Price vs fundamentals

How does MNPR's price correlate with its fundamentals

Growth

What is Monopar Therapeutics's growth rate over time

Valuation

What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
2.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 52% YoY but it has contracted by 4.3% from the previous quarter
The equity has soared by 153% YoY
MNPR's price to book (P/B) is 20% more than its 5-year quarterly average of 2.5 but 12% less than its last 4 quarters average of 3.4

Efficiency

How efficient is Monopar Therapeutics business performance
Monopar Therapeutics's ROIC has soared by 89% YoY and by 31% from the previous quarter
MNPR's return on equity has surged by 77% year-on-year and by 10% since the previous quarter
The return on assets has surged by 76% year-on-year and by 9% since the previous quarter

Dividends

What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNPR.

Financial health

How did Monopar Therapeutics financials performed over time
The total assets has surged by 150% year-on-year
The total liabilities has soared by 74% year-on-year but it has declined by 10% since the previous quarter
The company's debt is 100% lower than its equity
The equity has soared by 153% YoY
The company's debt fell by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.